论文部分内容阅读
软组织肉瘤是一组来源于间叶组织的恶性肿瘤,病理类型繁多。对于不可切除的局部晚期或转移性软组织肉瘤,以姑息性化疗为主的多学科综合治疗有利于减轻患者症状、延长总生存期和提高生活质量。蒽环类药物和异环磷酰胺仍是软组织肉瘤化疗的基石,近年来曲贝替定、艾瑞布林等新型化疗药物和培唑帕尼、Olaratumab等分子靶向药物相继问世,获批用于晚期软组织肉瘤的内科治疗,免疫检查点抑制剂PD-1/PD-L1单抗的异军突起,更是给晚期软组织肉瘤的免疫治疗带来了新的曙光。
Soft tissue sarcoma is a group of malignant tumors from mesenchymal tissue, a variety of pathological types. For unresectable, locally advanced or metastatic soft tissue sarcomas, palliative chemotherapy-based multidisciplinary therapy is beneficial for alleviating symptoms, prolonging overall survival and improving quality of life. Anthracyclines and ifosfamide are still the cornerstone of chemotherapy for soft tissue sarcoma. In recent years, many new chemotherapeutic agents such as trabectedin and iribulin have been published in succession, such as peizopanib and Olaratumab The medical treatment of advanced soft tissue sarcoma, the immune checkpoint inhibitor PD-1 / PD-L1 monoclonal antibody sudden emergence, but also to the late soft tissue sarcoma immunotherapy brought a new dawn.